

PTO/SB/08b (07-05)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Not Yet Assigned ハワワスト
				Filing Date	November 7, 2005
				First Named Inventor	Kang
				Art Unit	not yet assigned
	(Use as many sheets as ne	cessary)		Examiner Name	not yet assigned
Sheet	1	of	1	Attorney Docket Number	4240-130

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.							
	AA	FUKUOKA, Y., ET AL., Cloning and Characterization of the Guinea Pig C5a Anaphylatoxin Receptor: Interspecies Diversity among C5a Receptors, International Immunology, 1998, Page(s) 275-283, Volume 10, Publisher: Oxford University Press						
	AB	GANG, E.J., ET AL., In Vitro Mesengenic Potential of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells, Biochemical and Biophysical Research Communications, 7/9/2004, Page(s) 102-108, Volume 321, Number 1						
	AC	GANG, E.J., ET Al., Skeletal Myogenic Differentiation of Mesenchymal Stem Cells Isolated from Human Umbilical Cord Blood, Stem Cells, 2004, Page(s) 617-624, Volume 22, Number 4						
	AD	KIM, H.J., ET AL., Vascular Endothelial Growth Factor-Induced Andiogenic Gene Therapy in Patients with Peripheral Artery Disease, Experimental and Molecular Medicine, 2004, Page(s) 336, Volume 36, Number 4, Publisher: Korean Society of Medical Biochemistry & Molecular Biology						
	AE	LAOHAPENSANG, K., ET AL., Seasonal Variation of Buerger's Disease in Northern Part of Thailand, European Journal of Vascular and Endovascular Surgery, 10/1/2004, Page(s) 418-420, Volume 28, Number 4						
	AF	LEE, O.K., ET AL., Isolation of Multipotent Mesenchymal Stem Cells from Umbilical Cord Blood, Blood, 3/1/2004, Page(s) 1669-1675, Volume 103, Number 5						
	AG	MIYAMOTO, M. ET AL., Therapeutic Angiogenesis by Autologous Bone Marrow Cell Implantation for Refractory Chronic Peripheral Arterial Disease, Cell Transplant, 2004, Page(s) 429-437, Volume 13, Number 4						
	АН	YAMAMOTO, K., ET AL., Molecular Evaluation of Endothelial Progenitor Cells in Patients with Ischemic Limbs, Ateriosclerosis, Thrombosis, and Vascular Biology, 10/14/2004, Page(s) 192, Volume 24						
	AI	NICHOLSON, C.D., ET AL., The Effect of Physical Training on Rat Calf Muscle, Oxygen Tension, Blood Flow, Metabolism and Function in an Animal Model of Chronic Occlusive Peripheral Vascular Disease, Int. J. Sports Med., 1992, Jan, 13(1):60-4						

Date
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.